首页> 外文期刊>International journal of medicinal chemistry. >Synthesis of N-(6-(4-(Piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide Derivatives for the Treatment of Metabolic Syndrome
【24h】

Synthesis of N-(6-(4-(Piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide Derivatives for the Treatment of Metabolic Syndrome

机译:用于治疗代谢综合征的N-(6-(4-(哌嗪-1-基)苯氧基)吡啶-3-基)苯磺酰胺衍生物的合成

获取原文
           

摘要

Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγligand and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. Here we report synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives as an alternate remedy for insulin resistance.
机译:代谢综合征是一种广泛流行的多因素疾病,与心血管疾病和2型糖尿病的风险增加相关。由于胰岛素抵抗而导致的高血浆胰岛素和葡萄糖水平是代谢障碍的主要成分。噻唑烷二酮(TZD)是有效的PPARγ配体,在治疗2型糖尿病中用作胰岛素增敏剂。它们是有效的胰岛素增敏剂,但是由于诸如肝毒性之类的不利影响,迫切需要更安全的TZD替代品。在这里,我们报告的N-(6-(4-(哌嗪-1-基)苯氧基)吡啶-3-基)苯磺酰胺衍生物的合成作为胰岛素抵抗的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号